explore -WSS

explore

author：focus 2025-08-19 18:00:52 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： How the messy conversation about Dolly changed bioethics

entertainment

hotspot

WSS

House panel takes first step toward fixing drug shortages

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

FDA weighs limits of animal data in assessing artificial wombs

What happened to the House vote on health price transparency?

hotspot

explore

knowledge

Activists slam private health insurers over coverage restrictions

Akili changes sales model for its ADHD video game treatment

Affirmative action in medical school literally saved lives

People with substance use disorder deserve online privacy

In Memoriam: Notable people who died in 2023

Poor hospice wound care hurts patients and families

United colonoscopy coverage change 'may cost lives,' doctors say

Why the quest to eradicate polio has stumbled

United colonoscopy coverage change 'may cost lives,' doctors say

The struggle to figure out which patients 'deserve' Wegovy

leisure time

Morphosys mixed study results for blood cancer drug

Medicare to pay more for cardiac rehab in hospital outpatient clinics

NYU radiologists take on the challenge of expensive MRI machines

Why medical students are struggling with mental health

CRISPR pioneers react to Casgevy, first gene

Ransomware attacks on hospitals: Study outlines patient impact

entertainment

Wikipedia

hotspot

explore